Tfelt-Hansen P, Krabbe A
Department of Neurology, Rigshospitalet, Copenhagen, Denmark.
Cephalalgia. 1981 Mar;1(1):29-32. doi: 10.1111/j.1468-2982.1981.tb00005.x.
A follow-up study of 40 patients (migraine 39, cluster headache 1) previously treated for ergotamine abuse was conducted. Their statements regarding ergotamine intake were checked using butalbital (contained in the suppositories abused by 90% of the patients) as a tracer, and later by contact with the family doctor. Eleven patients abused ergotamine again during a median observation time of 21 months. Nineteen patients had more than a 50% reduction in headache days after withdrawal and half of the patients were relieved of other symptoms of ergotamine toxicity. Even with a failure rate of approximately 25% it is concluded that efforts to withdraw after abuse of ergotamine are worthwhile.
对40例曾因麦角胺滥用而接受治疗的患者（39例偏头痛患者，1例丛集性头痛患者）进行了一项随访研究。以布他比妥（90%的滥用栓剂患者所使用的栓剂中含有的成分）作为示踪剂，检查他们关于麦角胺摄入量的陈述，随后与家庭医生联系核实。在21个月的中位观察期内，11例患者再次滥用麦角胺。19例患者在停药后头痛天数减少了50%以上，半数患者的麦角胺中毒其他症状得到缓解。即使失败率约为25%，仍得出结论：滥用麦角胺后进行戒毒努力是值得的。
